Država: Švedska
Jezik: švedščina
Source: Läkemedelsverket (Medical Products Agency)
kabergolin
1A Farma A/S
G02CB03
cabergoline
0,5 mg
Tablett
laktos (vattenfri) Hjälpämne; kabergolin 0,5 mg Aktiv substans
Apotek
Receptbelagt
Kabergolin
Avregistrerad
2010-11-04
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT CABERGOLINE 1A FARMA 0.5 MG TABLETS cabergoline READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Cabergoline 1A Farma is and what it is used for 2. What you need to know before you take Cabergoline 1A Farma 3. How to take Cabergoline 1A Farma 4. Possible side effects 5. How to store Cabergoline 1A Farma 6. Contents of the pack and other information 1. WHAT CABERGOLINE 1A FARMA IS AND WHAT IT IS USED FOR Cabergoline 1A Farma belongs to a group of medicines known as prolactin inhibitors. Cabergoline 1A Farma prevents lactation (production of milk) by decreasing levels of a hormone known as prolactin. CABERGOLINE 1A FARMA can also be used to reduce abnormal quantities of the hormone prolactin in the blood. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE CABERGOLINE 1A FARMA DO NOT TAKE CABERGOLINE 1A FARMA IF YOU: are allergic to cabergoline or any of the other ingredients of this medicine (listed in section 6) have psychosis, or a history of psychosis, or you are at risk of psychosis after childbirth will be treated with Cabergoline 1A Farma for a long period and _have_ stiff and inflamed heart valves (cardiac valvulopathy) have ever been diagnosed in the past with a problem known as fibrosis affecting the lungs, lower back and kidneys or heart. WARNINGS AND PRECAUTIONS TALK TO YOUR DOCTOR OR PHARMACIST BEFORE TAKING CABERGOLINE 1A FARMA If you have any of the following health problems you must inform your doctor BEFORE taking Cabergoline 1A Fa Preberite celoten dokument
Produktinformationen för Cabergoline 1A Farma, 0,5 mg Tablett MTnr 42524, gäller vid det tillfälle då läkemedlet godkändes. Informationen kommer inte att uppdateras eftersom läkemedlet inte marknadsförs i Sverige. Av samma anledning finns inte någon svensk produktinformation. Den engelska produktinformationen kommer dock att uppdateras för de produkter där Sverige är referensland. Om läkemedelsnamnet i följande produktinformation inte stämmer med namnet på dokumentet, beror det på att läkemedlet i Sverige är godkänt under ett annat namn. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cabergoline 1A Farma, 0,5 mg, tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 0,5 mg cabergoline. Excipient(s): Each tablet contains 75, 9 mg anhydrous lactose For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet White, oval, uncoated, biconvex tablet, scored and debossed with “C 1/2“ on one side The tablet can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Inhibition of lactation for medical reasons. Hyperprolactimaemic disorders. Prolactin secreting pituitary adenomas. Idiopathic hyperprolactinaemia. It is recommended that the medicinal product is initially prescribed by an appropriate specialist or after consulting a specialist. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Cabergoline is to be administered by the oral route. In order to reduce the risk of gastrointestinal undesirable effects it is recommended that cabergoline is taken with meals for all therapeutic indications. The maximum dose is 3 mg cabergoline per day. Treatment of hyperprolactinaemic disorders. The recommended initial dosage of cabergoline is 0.5 mg per week given in one (single 0.5 mg) or two (separate 0.25 mg) doses (e.g. on Monday and Thursday) per week. The weekly dose should be increased gradually, preferably by adding 0.5 mg per week at monthly intervals until an optimal therapeutic response is achieved. The therapeutic dosage i Preberite celoten dokument